Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Cut to “Hold” at Zacks Research

Zacks Research lowered shares of Inovio Pharmaceuticals (NASDAQ:INO) from a strong-buy rating to a hold rating in a research report report published on Monday,Zacks reports.

A number of other brokerages have also commented on INO. Piper Sandler restated an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their target price for the company from $1.80 to $3.00 in a research note on Thursday, August 13th. Finally, HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, August 13th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Stock Down 9.7%

Inovio Pharmaceuticals stock opened at $1.00 on Monday. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.17. The stock has a market cap of $103.21 million, a price-to-earnings ratio of -1.10 and a beta of 1.61. Inovio Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. On average, analysts expect that Inovio Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in shares of Inovio Pharmaceuticals in the second quarter valued at about $33,000. Engineers Gate Manager LP acquired a new position in Inovio Pharmaceuticals during the 2nd quarter worth about $37,000. Squarepoint Ops LLC lifted its position in Inovio Pharmaceuticals by 46.5% during the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,554 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Inovio Pharmaceuticals by 1,929.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 46,536 shares during the last quarter. Finally, Green Alpha Advisors LLC grew its holdings in Inovio Pharmaceuticals by 68.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 46,802 shares during the last quarter. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (NASDAQ: INO) is a biotechnology company focused on developing DNA medicines, including immunotherapies and vaccines designed to stimulate targeted immune responses. Its technology platform uses synthetic DNA constructs delivered into cells, with the company’s CELLECTRA device platform developed to enhance cellular uptake.

Inovio’s pipeline has included candidates for infectious diseases, cancers and other conditions involving the immune system. Its lead programs have included INO-3107, an investigational DNA immunotherapy being developed for recurrent respiratory papillomatosis, and VGX-3100, an earlier candidate studied for human papillomavirus-related disease.